Skip to main content
SpringerLink
Log in

Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ACT:

Adoptive cell therapy

APM:

Antigen-presenting machinery

BM:

Bone marrow

CAR:

Chimeric antigen receptors

CDA:

Cytidine deaminase

CSC:

Cancer stem cells

DC:

Dendritic cells

DCR:

Disease control rate

DITC:

Dacarbazine

GIC:

Italian society of cytometry

GITR:

Glucocorticoid-induced tumor necrosis factor receptor

HF:

Heart failure

HMA:

Hypomethylating agent

ICI:

Immune checkpoint inhibitors

IDO1:

Indoleamine 2,3-dioxygenase-1

iNKT:

Invariant natural killer T cells

MDP:

Mutations and drugs portal

MDSC:

Myeloid-derived suppressor cells

MØ:

Macrophage orchestration

MSA:

Methylseleninic acid

MV:

Microvesicles

NSCLC:

Non-small cell lung cancer

ORR:

Objective response rate

OS:

Overall survival

PCa:

Prostate cancer

PDAC:

Pancreatic ductal adenocarcinoma

pDC:

Plasmacytoid dendritic cells

ROS:

Reactive oxygen species

STS:

Short-term starvation

TAM:

Tumor-associated macrophages

TCF-1:

Transgenic T-cell factor 1

TCR:

T-cell receptors

TENM4:

Teneurin-4

TIL:

Tumor-infiltrating lymphocytes

TLS:

Tertiary lymphoid structures

TME:

Tumor microenvironment

TNBC:

Triple-negative breast cancer

TNFR:

Tumor necrosis factor receptor

Treg:

Regulatory T cells

T-VEC:

Talimogene laherparepvec

Acknowledgements

This meeting was organized in collaboration with the Board of Directors of NIBIT and with NIBIT Foundation.

Funding

This meeting was supported in part by grants from Bristol-Meyers Squibb, Incyte, Merck Sharp & Dohme Corp. Oncology, Roche, Astex pharmaceuticals, Amgen, AstraZeneca and Merck Serono.

Author information

Authors and Affiliations

  1. Italian Network for Tumor Bio-immunotherapy (NIBIT), Siena, Italy

    Michele Maio & Vincenzo Russo

  2. Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, V.le Bracci, 16, Siena, Italy

    Michele Maio, Maria Fortunata Lofiego, Carolina Fazio, Sara Cannito, Carla Chiarucci, Gianluca Giacobini, Monica Valente, Patrizia Tunici & Alessia Covre

  3. University of Siena, Siena, Italy

    Sara Cannito

  4. Immuno-biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, San Raffaele Hospital Scientific Institute, Milan, Italy

    Vincenzo Russo

Authors
  1. Michele Maio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Fortunata Lofiego
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carolina Fazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sara Cannito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carla Chiarucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gianluca Giacobini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Monica Valente
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patrizia Tunici
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alessia Covre
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vincenzo Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Michele Maio, Maria Fortunata Lofiego, Carolina Fazio, Sara Cannito, Carla Chiarucci, Gianluca Giacobini, Alessia Covre contributed to writing the summary of the different meeting sessions; Vincenzo Russo, Monica Valente, Patrizia Tunici, Alessia Covre, and Michele Maio supervised and critically contributed to the final revision of the manuscript.

Corresponding author

Correspondence to Michele Maio.

Ethics declarations

Conflict of interest

Michele Maio is a consultant/advisory board member for Bristol-Meyers Squibb, Incyte, Merck Sharp & Dohme Corp. Oncology, Roche, Astex pharmaceuticals, Amgen, AstraZeneca and Merck Serono. No potential conflicts of interest were disclosed by the other authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maio, M., Lofiego, M.F., Fazio, C. et al. Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017. Cancer Immunol Immunother 68, 151–158 (2019). https://doi.org/10.1007/s00262-018-2222-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-018-2222-0

Keywords

Search

Navigation